Skyrocketing Cost of Obesity Drugs Has State Medicaid Programs Looking for Solutions

(MedPage Today) -- States increasingly struggling to cover the rising cost of popular GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are searching for ways to get out from under the budgetary squeeze...